wobenzym
mucos pharma gmbh & co. kg, nemecko - trypsín, kombinácie - 87 - varia i
stimuloton 50 mg
egis pharmaceuticals plc, maďarsko - sertralín - 30 - antidepressiva
hydrocortison vuab 100 mg
vuab pharma a.s., Česká republika - hydrokortizón - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
metopirone
hra pharma rare diseases, francúzsko - metyrapón - 48 - diagnostica
agomelatine sandoz 25 mg
sandoz pharmaceuticals d.d., slovinsko - agomelatín - 30 - antidepressiva
asthmex 50 mikrogramov/500 mikrogramov dávkovaný inhalačný prášok
glenmark pharmaceuticals s.r.o., Česká republika - salmeterol a flutikazón - 14 - bronchodilatantia, antiasthmatica
asthmex 50 mikrogramov/250 mikrogramov dávkovaný inhalačný prášok
glenmark pharmaceuticals s.r.o., Česká republika - salmeterol a flutikazón - 14 - bronchodilatantia, antiasthmatica
asthmex 50 mikrogramov/100 mikrogramov dávkovaný inhalačný prášok
glenmark pharmaceuticals s.r.o., Česká republika - salmeterol a flutikazón - 14 - bronchodilatantia, antiasthmatica
agomelatine glenmark 25 mg
glenmark pharmaceuticals s.r.o., Česká republika - agomelatín - 30 - antidepressiva
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcíny - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.